Inventiva resuscitates hopes for PPAR in NASH

PPAR had been largely written off as an effective mechanism for NASH after two PPAR agonists failed to show a benefit. Now, data for Inventiva’s lanifibranor show there may be life after all for the mechanism.

In addition to meeting the primary endpoint of a Phase II trial, the pan-PPAR agonist from Inventiva S.A. (Euronext:IVA) met the secondary endpoints that a compound must hit in Phase III to gain FDA and EMA approval for non-alcoholic steatohepatitis: NASH resolution with no worsening of fibrosis; and improvement of fibrosis with no worsening of NASH...